Angiogenesis: bench to bedside, have we learned anything?
End-stage ischemic cardiomyopathy patients are an ever-increasing group of coronary artery disease patients, often with no options in our current treatment armamentarium. Angiogenesis therapy pre-clinical and phase I clinical trials showed great promise, however, the benefits of single growth factor treatments have not been borne out in the larger phase II randomized trials. The complexity of angiogenesis process and the challenges in creating animal models to replicate and study this process in ischemic adult human myocardium have been major limitations to progress in this field. In addition failure to control for the powerful placebo effect in the clinical trials and inadequate methods of outcomes measures assessment have created difficult to overcome road blocks in establishing the efficacy of angiogenic strategies. Herein we review the challenges of angiogenesis research and development of treatment strategies. We also propose a structured model for further investigations of angiogenic therapies. The adherence to such a regimented approach as proposed here is, in our opinion, the only way to achieve success in angiogenesis approach development to treatment of patients with end-stage cardiac ischemia refractory to other established therapies.
Lee
Seung Uk
SU
Cardiovascular Division, BIDMC/Harvard Medical School, Boston, Massachusetts 02215, USA.
Wykrzykowska
Joanna J
JJ
Laham
Roger J
RJ
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology; D004195:Disease Models, Animal; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000473:pathology*; D042442:Vascular Endothelial Growth Factors / Q000494:pharmacology / Q000627:therapeutic use
D043925:Angiogenesis Inducing Agents; D042442:Vascular Endothelial Growth Factors